House Committee Asks Pfizer To Explain Celebrex Safety Defense
This article was originally published in The Pink Sheet Daily
Executive Summary
The House Energy & Commerce Committee is asking Pfizer to justify claims it made about Celebrex' safety profile following the withdrawal of Merck's Vioxx
You may also be interested in...
Pfizer Celebrex Polyp Trial Shows Increase In Cardiovascular Events
The Adenoma Prevention with Celecoxib trial found an increased CV risk for patients taking 400 mg and 800 mg Celebrex compared to placebo; a second study showed no increased risk. The APC study results mean Pfizer can no longer promote the COX-2 as being clear of cardiovascular signals.
Bextra Contraindicated In CABG Surgery Patients
Labeling change to add "black box" for serious skin reactions incorporates post-surgery safety data, including results from two coronary artery bypass graft trials that show increased cardiovascular risk with Pfizer's COX-2 inhibitor.
Pediatric Antidepressant Safety: “Jury Is Still Out,” FDA Tells Congress
Discussion of regulatory status of antidepressant indications is almost an afterthought during Sept. 9 House hearing. FDA’s Woodcock, however, stresses that agency is not ready to rule out a role for antidepressants in children.